Evidence map›Paper›PMID 38664714›Full record

ArticleBMC neurology2024

Taste disorders and alopecia in myasthenia gravis.

Akiyuki Uzawa, Shigeaki Suzuki, Satoshi Kuwabara, Hiroyuki Akamine, Yosuke Onishi, Manato Yasuda, Yukiko Ozawa, Naoki Kawaguchi, Tomoya Kubota, Masanori P Takahashi and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Evaluation of nonmotor symptoms in myasthenia gravis patients.Turkish journal of medical sciences · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 12 institutions in 1 country.

Akiyuki UzawaDepartment of Neurology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba-shi, Chiba, 260-8670, Japan. auzawa@chiba-u.jp.
Shigeaki SuzukiDepartment of Neurology, Keio University School of Medicine, Tokyo, Japan.
Satoshi KuwabaraDepartment of Neurology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba-shi, Chiba, 260-8670, Japan.
Hiroyuki AkamineDepartment of Neurology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba-shi, Chiba, 260-8670, Japan.
Yosuke OnishiDepartment of Neurology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba-shi, Chiba, 260-8670, Japan.
Manato YasudaDepartment of Neurology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba-shi, Chiba, 260-8670, Japan.
Yukiko OzawaDepartment of Neurology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba-shi, Chiba, 260-8670, Japan.
Naoki KawaguchiDepartment of Neurology, Neurology Chiba Clinic, Chiba, Japan.
Tomoya KubotaDepartment of Clinical Laboratory and Biomedical Sciences, Division of Health Sciences, Osaka University Graduate School of Medicine, Osaka, Japan.
Masanori P TakahashiDepartment of Clinical Laboratory and Biomedical Sciences, Division of Health Sciences, Osaka University Graduate School of Medicine, Osaka, Japan.
Yasushi SuzukiDepartment of Neurology, National Hospital Organization Sendai Medical Center, Sendai, Japan.
Genya WatanabeDepartment of Neurology, National Hospital Organization Sendai Medical Center, Sendai, Japan.
Takashi KimuraDepartment of Neurology, Hyogo Medical University, Nishinomiya, Japan.
Takamichi SugimotoDepartment of Clinical Neuroscience and Therapeutics, Hiroshima University, Hiroshima, Japan.
Makoto SamukawaDepartment of Neurology, Kindai University Faculty of Medicine, Osakasayama, Japan.
Naoya MinamiDepartment of Neurology, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan.
Masayuki MasudaDepartment of Neurology, Tokyo Medical University, Tokyo, Japan.
Shingo KonnoDepartment of Neurology, Toho University Ohashi Medical Center, Tokyo, Japan.
Yuriko NaganeDepartment of Neurology, Hanamaki General Hospital, Hanamaki, Japan.
Kimiaki UtsugisawaDepartment of Neurology, Hanamaki General Hospital, Hanamaki, Japan.
Chiba University · JPNational Hospital Organization Hanamaki Hospital · JPSendai Medical Center · JPThe University of Osaka · JPChiba Hospital · JPHiroshima University · JPHyogo University · JPKeio University · JPKindai University · JPNational Hospital Organization Hokkaido Medical Center · JPToho University · JPTokyo Medical University · JP

Funding

Health and Labour Sciences Research Grant on Intractable Diseases (Neuroimmunological Diseases) from the Ministry of Health, Labour and Welfare of Japan 20FC1030
6 · The paper itself

Abstract

backgroundNon-motor symptoms in myasthenia gravis (MG) are rarely confirmed. Although there are some small cohort studies, a large-systemic survey has not yet been performed.

methodsWe investigated the incidence and clinical characteristics of patients with MG who had taste disorders and alopecia using data of 1710 patients with MG enrolled in the Japan MG Registry 2021.

resultsAmong them, 104 (6.1%) out of 1692 patients and 138 (8.2%) out of 1688 patients had histories of taste disorders and alopecia, respectively. Among the patients with MG, taste disorders were significantly more common in women, those with severe symptoms, refractory MG, or thymoma-associated MG, and were less common in those with ocular MG. The taste disorders often occurred after the onset of MG and often responded to MG treatments. Alopecia was more common in MG patients with a history of bulbar palsy and thymoma, and it often occurred before the onset of MG and sometimes responded to MG treatments. Multivariate logistic regression analysis revealed taste disturbance was associated with worst quantitative MG score and thymoma-associated MG; and alopecia was associated with thymoma-associated MG.

conclusionClinicians should be aware of the non-motor symptoms in MG, especially in patients with severe myasthenic symptoms and thymoma-associated MG.

Indexed as

AlopeciaMyasthenia GravisTaste DisordersAdultAgedFemaleHumansIncidenceJapanMaleMiddle AgedRegistriesThymomaAlopeciaNon-motor symptomsRefractoryTaste disordersThymoma

Identifiers

PMID38664714
PMCPMC11044552
OpenAlexW4395456084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.